Literature DB >> 1334755

Effects of PAF on excitatory neuro-effector transmission in dog airways.

K Tashiro1, Z Xie, Y Ito.   

Abstract

1. Effects of PAF on excitatory neuro-effector transmission in smooth muscle cells of mucosa-free trachea and epithelium-intact bronchiole of the dog were investigated, by isometric tension recording, microelectrode and double sucrose-gap methods. 2. PAF (10(-11)-10(-7) M) dose-dependently enhanced the amplitude of contraction evoked by repetitive field stimulations (10 stimuli at 20 Hz) in both tracheal and bronchiolar tissues. At higher concentrations PAF (> 10(-8) M) increased the amplitude of contraction to a greater extent in the bronchiole than in the trachea. 3. In both muscle tissues, in parallel to the amplitude of contraction, PAF markedly enhanced the amplitude of excitatory junction potentials (e.j.ps) evoked by a single field stimulation in a dose-dependent manner, with no change in the resting membrane potential or input membrane resistance of the smooth muscle cells. PAF (5 x 10(-7) M) enhanced the amplitude of e.j.p. to a greater extent in the bronchiole than in the trachealis. In contrast, lyso-PAF (10(-10)-10(-7) M) showed no effect on e.j.p. amplitude in bronchiolar tissues. At a high concentration (10(-7) M) lyso-PAF slightly enhanced the e.j.p. amplitude in tracheal tissue, however the lyso-PAF induced stimulation of e.j.p. amplitude in the trachea was small compared to that of PAF. 4. PAF (10(-7) M) had no effect on the membrane depolarization induced by acetylcholine (ACh, 10(-9)-10(-5) M) and carbachol (10(-9)-10(-5) M) in tracheal smooth muscle cells. 5. The PAF-antagonists CV3988 (5 x i0-7 M) or WEB2086 (5 x 10-7 M) significantly enhanced the e.j.p. amplitude themselves, PAF (5 x 10-8 M) further enhanced the ej.p. amplitude in the presence of WEB2086 (5 x l0-7 M) but not CV3988 (5 x 10-7 M). In contrast, the new PAF-antagonist, E 6123(5 x l0-8 M), did not affect the ej.p. amplitude itself, and completely inhibited the increase in ej.p. amplitude caused by 5 x 10-8 M PAF. On the other hand, in the presence of the Hi-antagonist,mepyramine, PAF (5 X 10-8 M) further enhanced the ej.p. amplitude.6. The leukotriene synthesis inhibitor AA-861 (10-6 M) or leukotriene antagonist ONO1078 (10-7 M)inhibited the increase in ej.p. amplitude caused by 5 X 10-8 M PAF, respectively.7. In the presence of AA-861 (10-6 M), leukotriene B4 (LTB4, 10-' M) or LTD4 (10-8 M) slightly, and LTC4 (10- M) markedly enhanced the ej.p. amplitude. In contrast, LTE4 (10-8 M) significantly suppressed the e.j.p. amplitude.8. PAF (5 x 10-8 M) attenuated the depression phenomena of ej.ps observed during double stimulus experiments at different time intervals (5-10 s), but had no effect on the summation of ej.ps during repetitive field stimulation at a high frequency (20 Hz) in the trachealis.9. These results indicate that PAF potentiates excitatory neuro-effector transmission mainly through stimulating the release of lipoxygenase products, mainly LTC4 in the dog airway smooth muscle tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334755      PMCID: PMC1907945          DOI: 10.1111/j.1476-5381.1992.tb13391.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

Review 1.  Platelet-activating factor and airway reactivity.

Authors:  R G Townley; R J Hopp; D K Agrawal; A K Bewtra
Journal:  J Allergy Clin Immunol       Date:  1989-06       Impact factor: 10.793

Review 2.  Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline-phospholipids.

Authors:  F Snyder
Journal:  Med Res Rev       Date:  1985 Jan-Mar       Impact factor: 12.944

3.  Inhaled PAF stimulates leukotriene and thromboxane A2 production in humans.

Authors:  I K Taylor; P S Ward; G W Taylor; C T Dollery; R W Fuller
Journal:  J Appl Physiol (1985)       Date:  1991-10

4.  Mechanism of platelet activating factor-induced bronchoconstriction in humans.

Authors:  L J Smith; A H Rubin; R Patterson
Journal:  Am Rev Respir Dis       Date:  1988-05

5.  The effect of platelet activating factor on pulmonary beta-adrenoceptors.

Authors:  P J Barnes; B M Grandordy; C P Page; K J Rhoden; D N Robertson
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

6.  Modulation of cholinergic neurotransmission by the peptide VIP, VIP antiserum and VIP antagonists in dog and cat trachea.

Authors:  H Hakoda; Y Ito
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

7.  Paf-induced release of spasmogens from guinea-pig lungs.

Authors:  S Jancar; P Thériault; M Lauzière; P Braquet; P Sirois
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

8.  The effect of platelet-activating factor on histamine and muscarinic receptor function in guinea pig airways.

Authors:  D N Robertson; A J Coyle; K J Rhoden; B Grandordy; C P Page; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1988-06

9.  Contracture and change in membrane potential produced by sodium removal in the dog trachea and bronchiole.

Authors:  Y Ito; T Inoue
Journal:  J Appl Physiol (1985)       Date:  1989-11

10.  Characteristics of neuro-effector transmission in the smooth muscle layer of dog bronchiole and modifications by autacoids.

Authors:  T Inoue; Y Ito
Journal:  J Physiol       Date:  1986-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.